Literature DB >> 8062494

Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.

M L Dahl1, G Tybring, C E Elwin, C Alm, K Andreasson, M Gyllenpalm, L Bertilsson.   

Abstract

The pharmacokinetics of mianserin and its main metabolite desmethylmianserin were studied in poor and extensive metabolizers of debrisoquin and of S-mephenytoin after a single oral dose of racemic mianserin. The debrisoquin metabolic ratio (MR) correlated significantly with area under the serum concentration-time curves (AUC) for (+/-)-mianserin and (+/-)-desmethylmianserin. Enantioselective high-performance liquid chromatographic analysis of mianserin showed that debrisoquin MR was related to AUC(0-12) for S(+)-mianserin (rs = 0.87; p = 0.001; n = 15) but not for R(-)-mianserin. The ratio between the AUC(0-12) for S(+)-mianserin and that for R(-)-mianserin was higher in poor metabolizers than in extensive metabolizers. Two extremely rapid extensive metabolizer subjects had the lowest mianserin S/R ratios. No differences in the pharmacokinetics of mianserin or desmethylmianserin were found between extensive metabolizers and poor metabolizers of S-mephenytoin. The study shows that the elimination of both mianserin and its main metabolite desmethylmianserin is dependent on CYP2D6 activity. Furthermore, the CYP2D6-dependent elimination of mianserin shows marked enantioselectivity for the more active S(+)-enantiomer of mianserin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8062494     DOI: 10.1038/clpt.1994.121

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

Review 1.  Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Authors:  S Rotzinger; M Bourin; Y Akimoto; R T Coutts; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 3.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

4.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 5.  Chirality and drugs used in psychiatry: nice to know or need to know?

Authors:  R M Lane; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases.

Authors:  L Karlsson; A-L Zackrisson; M Josefsson; B Carlsson; H Green; F C Kugelberg
Journal:  Pharmacogenomics J       Date:  2014-09-23       Impact factor: 3.550

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.